01.12.2021 - PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) - Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to .
NEW ORLEANS — Patients with dry eye disease saw improvements in symptoms and signs after treatment with varenicline nasal spray, according to a study presented at the American Academy of Ophthalmology meeting. Marjan Farid, MD, said Tyrvaya (varenicline solution, Oyster Point Pharma), formerly known as OC-01, is a cholinergic agonist that leads to an increase in basal tear production
Adagio Therapeutics (ADGI) Announces Expansion of Management Team and Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.